-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下:通用电气航空航天公司公布了2026年第一季度强劲的业绩,调整后每股收益为1.86美元(同比增长25%),超出市场预期0.26美元;营收同比增长29%至116亿美元,超出预期8.99亿美元。总订单额同比增长87%至230亿美元,反映出航空业需求的持续强劲以及FLIGHT DECK计划的运营进展。由于售后市场需求强劲,且材料供应有所改善,商业服务收入同比增长39%,但由于初期交付的GE9X飞机利润率较低,商业服务利润率下降230个基点至26.4%。管理层表示有信心实现2026年每股收益预期(7.10美元至7.40美元区间)的高端目标。国防业务收入同比增长19%,订单同比增长67%,自由现金流达到17亿美元(同比增长14%)。1700亿美元的商业服务积压订单为未来多年提供了可观的收入前景。我们认为第一季度强劲的业绩支撑了我们的“买入”评级,同时我们也注意到,较高的预期市盈率是基于公司持续强劲的业绩执行和商业航空业务的持续复苏而设定的。
Related Articles
Biocytogen Pharmaceuticals Turns to Profit in Q1
Biocytogen Pharmaceuticals (Beijing) (HKG:2315) recorded an attributable profit of 104 million yuan in the first quarter of 2026, compared with an attributable loss of 13.2 million yuan a year prior, according to a Monday Hong Kong bourse filing.Earnings per share stood at 0.23 yuan, compared with a loss per share of 0.03 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 74% in the three months to 433.1 million yuan from 249.3 million yuan in the year-ago period, driven by a substantially higher revenue contribution from pharmacology and efficacy services and animal models.The pharmaceutical company attributed the higher profit mainly to revenue growth and improved operating efficiency amid expense management.
Market Chatter: LNG Carrier Orders Surge as Global Output Defies Iran War Tensions
Global demand for liquefied natural gas carriers is rebounding sharply in 2026, despite the ongoing US-Iran conflict, Reuters reported Monday, citing analysts and industry experts.Analysts report that surging LNG production and a transition toward high-efficiency vessels are fueling the recovery.According to the report, Shipbuilders in South Korea and China have already secured 35 new build contracts in Q1 alone.The resurgence in construction comes despite the escalating US-Iran war, which has choked the Strait of Hormuz and raised fears of a prolonged shipping downturn.However, market experts suggest that the need for modern, fuel-efficient tonnage is outweighing immediate freight rate concerns, it said.These new vessels, which cost between $250 million and $260 million and take over three years to complete, are increasingly necessary as older, steam-propelled tankers are scrapped at record rates to meet stricter global emissions regulations.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Canaccord Genuity Initiates Coverage on Structure Therapeutics With Buy Rating, $101 Price Target
Structure Therapeutics (GPCR) has an average rating of Buy and mean price target of $108.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)